FDA Clears Pioneering MeMed BV Test Direct from Whole Blood Allowing Faster Time to Result and Broader Patient Access when Distinguishing Bacterial from Viral Infections Read more...
Read MoreAlmost every sports team has some version of a stadium or team app, usually developed by one of the main third-party providers in the market. These vary in quality and functionality, with most teams trying hard to engage fans by supporting digital ticketing and payment and loyalty services inside the app, with varying degrees of success in getting fans to download and use the programs. Read...
Read MoreSAN DIEGO, CALIFORNIA, UNITED STATES, July 19, 2023/EINPresswire.com/ — Verse.io, the market leader in conversational AI for business texting and customer outreach, is pleased to announce the appointment of Damien Swendsen as its new Senior Vice President of Revenue. With over two decades of technology sales experience and a proven track record of success, Damien will play a pivotal role in driving Verse’s growth, expanding its customer base, establishing strategic partnerships, and strengthening the company’s brand presence. Read...
Read MoreANAHEIM, Calif., July 19, 2023 /PRNewswire/ — Beckman Coulter, a global leader in clinical diagnostics, today announced it will debut its hematology analyzer and slidemaker stainer connected to Scopio Labs’ digital morphology platform for end-to-end digitization with artificial intelligence-assisted peripheral blood smear analysis at the 2023 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo. The solution features the Beckman Coulter DxH 900 Workcell and DxH Slidemaker Stainer II connected with the Scopio X100HT digital morphology platform capable of continuous loading, scanning and analysis. Read more...
Read MoreTOKYO, EMERYVILLE, Calif. and COLUMBIA, Md., July 18, 2023 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Eko Health Inc. (Co-Founder and CEO: Connor Landgraf, “Eko”) announced today that they have entered into a License & Supply Agreement for the global supply and license of Eko’s latest digital stethoscope, the CORE 500™, and a custom suite of Eko’s AI-powered cardiovascular disease detection software. Working collaboratively with Welldoc, Inc. (President, CEO: Kevin McRaith, “Welldoc”), Astellas intends to integrate Eko’s technology with Welldoc’s cardiometabolic digital therapeutic (DTx) capabilities to create a proprietary, non-invasive device-DTx solution for patients with heart failure, currently known as Z1608. Astellas intends to seek U.S. Food and Drug Administration (FDA) clearance for Z1608. Read...
Read More
